Structure Therapeutics Appoints Experienced COO & General Counsel Matthew Lang

summarizeSummary

Structure Therapeutics announced the appointment of Matthew Lang as Chief Operating Officer and General Counsel, bringing extensive biopharmaceutical leadership experience to the company as it advances its lead obesity drug into Phase 3.

check_boxKey Events

• New C-Suite Appointment

  Matthew Lang was appointed Chief Operating Officer and General Counsel, effective April 15, 2026.

• Extensive Industry Experience

  Mr. Lang brings over 15 years of executive leadership from global biopharmaceutical organizations, including Metsera (involved in a $10 billion acquisition by Pfizer), Lyell Immunopharma, Myovant Sciences (commercialization of Myfembree® and Orgovyx®), and Gilead Sciences.

• Strategic Timing for Phase 3 Advancement

  The appointment comes as Structure Therapeutics prepares to advance its lead obesity drug, aleniglipron, into Phase 3, leveraging Mr. Lang's expertise in global operations, strategic transactions, and commercialization.

• Compensation Package Detailed

  Mr. Lang will receive a base salary of $560,000, a target annual bonus of 40% of base, and equity awards including options for 74,592 ADSs, time-based RSUs for 61,538 ADSs, and performance-based RSUs for 15,385 ADSs at target levels.

auto_awesomeAnalysis

The appointment of Matthew Lang as Chief Operating Officer and General Counsel is a strategic move for Structure Therapeutics, particularly as the company prepares to move its lead obesity drug, aleniglipron, into Phase 3 clinical development. Mr. Lang's background, which includes guiding a biopharmaceutical company through a significant acquisition and leading commercialization efforts, aligns well with Structure Therapeutics' growth trajectory and future operational needs. This strengthens the executive team and signals a focus on scaling operations and strategic execution.